Is NCT03215498 results overdue?

Yes — results are overdue. Primary completion was 2017-11-20; the FDAAA-801 reporting deadline (2018-11-20) passed 2770 days ago and no results are posted on ClinicalTrials.gov.

A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes

NCT ID	NCT03215498 ↗
Sponsor	Novo Nordisk A/S (INDUSTRY)
Public issuer	NOVO NORDISK A S — NVO (CIK 0000353278) best-effort name match, 95% conf — verify on EDGAR ↗
Phase	PHASE1
Status	COMPLETED
Primary completion	2017-11-20 (ACTUAL)
Reporting deadline	2018-11-20 (completion + 365d)
Days overdue	2770
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `ab259d1a8fac787f…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03215498. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.